Table 2 Patient characteristics in ED-SCLC according to timepoint of start of irradiation

Sex

Male

5 (71.43)

5 (83.33)

35 (62.50)

Female

2 (28.57)

1 (16.67)

21 (37.50)

Age

Average

63.99

49.96

63.91

Range

52–76

38–68

39–85

Karnofsky performance status

Median

70

85

70

50–70

5 (71.43)

2 (33.33)

36 (64.29)

80–100

2 (28.57)

4 (66.67)

20 (35.71)

Chemotherapy regimens

CE (platinum derivatives/etoposide)

6 (85.71)

3 (50.00)

33 (58.93)

CEA (platinum derivatives/etoposide/ antibodies)

1 (14.29)

2 (33.33)

8 (14.29)

Others

0 (0.00)

1 (16.67)

15 (26.79)

Time to irradiation

Median in days

30

83

183

Range

14–181

43–398

79–553

Concepts of doses

2 Gy up to 50 Gy

1 (14.29)

2 (33.33)

24 (42.86)

2 Gy up to 50 Gy + 10 Gy Boost

2 (28.57)

2 (33.33)

7 (12.50)

2.5 Gy up to 40 Gy

0 (0.00)

0 (0.00)

9 (16.07)

2.5 Gy up to 50 Gy

1 (14.29)

1 (16.67)

10 (17.86)

Others

4 (56.58)

1 (16.67)

19 (33.93)

Mean lung dose in Gy

Median

10.92

16.12

13.47

Range

1.72–14.58

9.95–23.04

2.90–21.44

Prophylactic cranical irradiation

0 (0.00)

0 (0.00)

0 (0.00)

Toxicity at leats 1

4 (56.58)

6 (100.00)

40 (71.43)

Remission status after thoracic radiation

Not stated

0 (0.00)

0 (0.00)

6 (10.71)

Stable

0 (0.00)

0 (0.00)

3 (85.36)

Partial remission

5 (41.43)

5 (83.33)

14 (25.00)

Complete remission

0 (0.00)

0 (0.00)

6 (10.71)

Progressive disease

2 (28.57)

1 (16.67)

27 (48.21)

Progression-free survival (PFS) in month

Median after date of diagnosis

6.4 (3.6–9.1)

13.0 (6.9–19.1)

12.2 (9.6–14.7)

Median after thoracic radiation

3.1 (0.0–7.6)

2.7 (0.0–10.0)

2.3 (1.4–3.3)

Overall survival (OAS) in month

Median after date of diagnosis

4.3 (0.0–11.7)

39.4 (0.0–92.8)

12.1 (11.2–13.0)

Median after thoracic radiation

1.4 (0.0–4.0)

31.5 (0.0–93.3)

4.6 (3.8–5.5)

2-year overall survival rate after date of diagnosis

0 (0.00)

3 (50.00)

5 (8.93)